Brokerages Anticipate Senesco Technologies Inc. (ELOX) to Announce ($0.37) EPS
Senesco Technologies Inc. (NYSE:ELOX) has earned an average broker rating score of 1.40 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and four have given a strong buy recommendation to the company. Senesco Technologies’ rating score has declined by 40% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokers have set a 12-month consensus price target of $20.00 for the company and are anticipating that the company will post ($0.37) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Senesco Technologies an industry rank of 58 out of 256 based on the ratings given to its competitors.
Separately, HC Wainwright restated a “neutral” rating on shares of Senesco Technologies in a research report on Monday, December 24th.
Senesco Technologies (NYSE:ELOX) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03.
About Senesco Technologies
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Senesco Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies and related companies with MarketBeat.com's FREE daily email newsletter.